All lobbying filings

BRISTOL-MYERS SQUIBB COMPANY

BRISTOL-MYERS SQUIBB COMPANY filed a Q2 report for BRISTOL-MYERS SQUIBB COMPANY on July 21, 2025.

Lobbying for BRISTOL-MYERS SQUIBB COMPANY

All filings by BRISTOL-MYERS SQUIBB COMPANY · Everything BRISTOL-MYERS SQUIBB COMPANY has reported

Filing · LD-2 quarterly report Q2 report

Reporting period

2nd Quarter 2025

Apr 1 - June 30 · Posted Jul 21, 2025

Expenses

$4,780,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

District of Columbia

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 6

Health Issues

H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act Discussions regarding H.R.1, One Big Beautiful Bill Act regarding bio-pharmaceutical provisions

Medicare/Medicaid

Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions Issues related to the six protected classes of medicines under Medicare Part D, regarding all bio-pharmaceutical issues

Taxation/Internal Revenue Code

Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation

Intellectual Property Reform concerning bio-pharmaceutical industry

Pharmacy

S.864, HELP Copays Act S.526, Pharmacy Benefit Manager Transparency Act of 2025 H.R.3285, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act Modernizing and Ensuring Equity Act H.R.3521, Clinical Trials Modernization Act Discussions regarding Continuing Resolution to include PBM reform, H.R.1968

Trade (domestic/foreign)

International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues

Bills named in this filing 8

H.R. 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
H.R. 1
One Big Beautiful Bill Act
S. 864
HELP Copays Act
S. 526
Pharmacy Benefit Manager Transparency Act of 2025
H.R. 3285
Fairness for Patient Medications Act
S. 1339
Pharmacy Benefit Manager Reform Act
H.R. 3521
Clinical Trial Modernization Act
H.R. 1968
Full-Year Continuing Appropriations and Extensions Act, 2025

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.